A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.

@article{Voss2016API,
  title={A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.},
  author={Tiffini Voss and Richard B. Lipton and David W Dodick and Nicole Dupre and Joy Yang Ge and Robert A. Bachman and Christopher A Assaid and Sheena K. Aurora and D. Michelson},
  journal={Cephalalgia : an international journal of headache},
  year={2016},
  volume={36 9},
  pages={887-98}
}
AIM The aim of this trial was to evaluate the efficacy and tolerability of ubrogepant (MK-1602), a calcitonin gene-related peptide receptor antagonist (CGRP-RA), for the acute treatment of migraine. METHODS This double-blind, placebo-controlled study randomized 834 participants to treat one migraine attack with ubrogepant 1 mg, 10 mg, 25 mg, 50 mg, 100 mg, or placebo in a 1:1 ratio. The co-primary endpoints were pain freedom and headache response at two hours. The first primary hypothesis… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
33 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…